The veterinary-grade active pharmaceutical ingredient described as Yinzhi Jiedu Granules Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a dry herbal extract granulate rather than a raw botanical powder. Its intended position in the production chain is as a partially standardized active ingredient that can be dry-blended, wet-granulated, filled into hard gelatin capsules, compressed into tablets, dispersed into oral powders or premixes, or dissolved and filtered for injection-grade solutions. The presence of a supplier-applied granulation step reduces the segregation tendency observed with fine herbal powders during high-shear mixing and direct compression. However, the specific granule density, friability, and hygroscopicity are product-specific and must be taken from the manufacturer’s certificate of analysis. For the same reason, a universal model designation is not assigned across suppliers; batch-specific identifiers and the manufacturing site code replace a fixed commercial model number.

What Pharmacopoeial Boundary Conditions Apply to a Multi-Dosage Form Veterinary Herbal API?

Pharmacopoeial alignment depends on target market. In the People’s Republic of China, the relevant framework is the Chinese Veterinary Pharmacopoeia, supplemented by Chinese Pharmacopoeia general chapters for non-sterile products. For products exported to the European Union, the European Pharmacopoeia general method 2.6.14 for bacterial endotoxins and general chapter 5.1.4 for microbiological quality of non-sterile products may apply alongside Regulation (EU) 2019/6. In the United States, safety verification of veterinary drug substances may require alignment with 21 CFR Part 211 for current good manufacturing practice when the material is used in a finished pharmaceutical. Residual solvent testing is commonly reported according to USP <467> or Ph. Eur. 2.4.24, while elemental impurity analysis is aligned with ICH Q3D using inductively coupled plasma-mass spectrometry. A critical operational distinction is that feed-grade herbal powders are generally evaluated under feed additive criteria such as sensory appearance, moisture, and total ash; they are not automatically acceptable as a veterinary-grade API for injectable preparation without additional purification and endotoxin reduction.

The upstream extraction history influences the API’s performance downstream. When the Yinzhi Jiedu formula is prepared as an aqueous decoction, concentration under reduced pressure below 70 °C is often used to preserve heat-sensitive marker constituents. The concentrated extract may be dried by spray drying or vacuum belt drying. Spray-dried extracts may exhibit bulk density values in the range 0.35 g/cm³ to 0.65 g/cm³ before granulation, while vacuum-belt-dried extracts can produce higher density but require milling. These differences affect the final granulate’s compressibility and rehydration. Manufacturers should request the drying method, native extract ratio, and excipient composition from the supplier. If maltodextrin is used as a drying carrier, this constituent can increase hygroscopicity and alter the glass transition temperature; formulators must verify that the API’s amorphous content does not cause caking when stored in tropical climates. Published data for this specific configuration is limited, and any scale-up from laboratory to production should include a moisture sorption isotherm study at 25 °C and 60% RH.

Botanical raw materials used in veterinary APIs carry an inherent microbial burden and may contain aflatoxins, ochratoxin A, or pesticide residues. A veterinary-grade API is distinguished from a simple dried decoction by the inclusion of a validated steam sterilization or gamma irradiation step for the raw botanical powder, or by terminal heat treatment of the extract. The microbial limit test for oral granules may apply total aerobic microbial count and total yeast/mould count limits aligned with the Chinese Veterinary Pharmacopoeia or Ph. Eur. 5.1.4. When the material is intended for parenteral use, it must also meet a bacterial endotoxin limit and, after reconstitution, a sub-visible particulate count. These requirements are not automatically satisfied by feed-grade material; a certificate of analysis that lists only moisture and total ash is insufficient for pharmaceutical use.

Injection Grade Clarification, Endotoxin, and Particulate Matter Constraints

Use of a herbal extract granulate in an injectable solution imposes stricter limits than oral powder use. After reconstitution in Water for Injection, the solution must pass a clarity check and a particle burden method such as USP <788> or Ph. Eur. 2.9.19. The starting API should be evaluated for cold-water solubility, pH shift after reconstitution, and the presence of high-molecular-weight colloidal material that can foul sterilizing-grade membrane filters. Bacterial endotoxin control is route-dependent. An oral granule may tolerate a higher endotoxin load than an intravenous solution; typical injectable herbal-API release limits may require endotoxin acceptance criteria not more than 0.25 EU/mg to 0.5 EU/mg when the maximum clinical dose is known. If the final product is not terminally sterilized, the API must be processed in an aseptic environment after sterile filtration through a 0.22 µm membrane. The API is not considered sterile in its standard supply form; terminal sterilization of the finished solution is preferred where the active marker compounds are thermostable.

For oral powders and premixes, the product’s bulk density and dusting tendency are the controlling variables. Horizontal ribbon blenders and ploughshare mixers commonly require an excipient pre-blend step to avoid the formation of API-rich agglomerates when granules are loaded before a fine carrier such as dextrose monohydrate. Complete batch homogeneity is monitored by sampling from at least 10 points across the blender following a validated mixing time, with assay relative standard deviation typically expected to be not more than 5.0%. In oral solutions, the presence of non-dissolved particles from botanical extract may require pre-clarification through 1 µm or 0.45 µm filters before final packaging. The contrast with conventional single-chemical veterinary APIs is most evident here: the extract matrix contains polysaccharides, tannins, and mineral residues that can increase viscosity and reduce chemical stability in aqueous media. Chelating agents or pH buffers may be needed to maintain marker compound recovery over the labelled shelf life.

When High-Speed Rotary Tablet Presses and Capsule Filling Machines Are Used

At production rates above 60,000 tablets/h on a rotary press, the granulated API must possess sufficient compactability and low sticking tendency. Magnesium stearate addition at 0.5% to 1.0% is a common lubrication range, but over-lubrication can reduce tensile strength when the extract granulate contains hydrophobic components. A precompression force setting is often required to remove entrapped air from herbal granulate because its lower bulk density can cause capping at high turret speeds. Capsule filling on an automatic machine benefits from a granulate with a Carr index below 25 and Hausner ratio below 1.25; values above these thresholds typically indicate the need for a re-granulation or additional glidant. Differences from other products become operational at this stage: a purified synthetic API may flow and compress predictably after simple blending, while the multi-component extract granulate requires batch-specific adjustment of compression force, punch penetration, and turret speed.

Dissolution testing of tablets containing this extract granulate requires careful selection of the dissolution medium. Because the granulate contains multiple botanical constituents with differing pKa and solubility profiles, a single marker compound may not represent the full matrix. The product developer should establish an in-house dissolution method with pH 1.2, pH 4.5, and pH 6.8 media using USP apparatus 2 at 50 rpm or USP apparatus 1 at 100 rpm, and report the cumulative release at 15 min, 30 min, and 45 min. However, published data for this specific formulation is limited; method validation must be conducted under the target market’s veterinary regulatory guidance. The difference from chemically defined APIs is that botanical marker compounds may bind to proteins or complex with metal ions in the medium, producing apparent incomplete release unless the analytical method includes an extraction or hydrolysis step.

Compared with feed-grade Yinzhi Jiedu powders, the veterinary-grade API is expected to be manufactured under pharmaceutical quality systems with controlled rooms, validated cleaning, and batch traceability. The residual moisture, total ash, heavy metals, microbial enumeration, and marker compound assay are all tighter than feed supplement specifications. Compared with a single-entity synthetic veterinary API, the multi-component extract granulate displays broader particle size distribution and higher hygroscopicity; thus its storage in unopened aluminium-foil bags with desiccant is preferred. Compared with human-grade herbal APIs, the veterinary-grade material may allow a different impurity profile, but the same injectable-grade requirement for bacterial endotoxin and sterility of the finished product applies. Material intended only for oral granule or premix use must not be assumed suitable for injection without a documented endotoxin reduction step and filtration validation. The absence of published stability data for each mixture of dosage-form excipients means each formulation must be placed on a bracketed or matrix stability protocol according to the target market’s veterinary regulatory authority.